Background: Anderson et al. 1,2 proposed that β 2 -adrenoceptor agonists taken by inhalation were superior to tablets for inhibiting exercise-induced bronchoconstriction (EIB) because sufficiently high concentration of drug was delivered directly to the airway to prevent mediator release from mast cells. Aim: The aim of this study was to investigate the effect of a clinically recommended dose of β 2 -adrenoceptor agonist on mast cell activation in response to dry air hyperpnoea in athletes with EIB. Methods: A randomized, double blind, placebo controlled, cross over design in 18 subjects. Terbutaline (0.5 mg) or placebo was inhaled 15 min before 8 min of eucapnic voluntary hyperpnoea (EVH) with dry air at 80% predicted maximum ventilation. The response to EVH was measured as the maximum % fall in FEV 1 from baseline after EVH. Mast cell activation was measured by urinary 11β-prostaglandin(PG)F 2α concentrations at baseline and 30, 60 min post-EVH.
